Ayala Pharmaceuticals to Present at the 2022 Jefferies Global Healthcare Conference

Rhea-AI Summary

Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA) will participate in a "Fireside Chat" at the Jefferies Healthcare Conference from June 8-10, 2022, in New York, NY. The presentation is scheduled for June 10, 2022, from 12:15 PM to 12:40 PM EST at the Marriott Marquis. Ayala focuses on developing small molecule therapeutics for rare and aggressive cancers, using a bioinformatics platform and next-gen sequencing to target tumorigenic drivers. The webcast will be available on Ayala's website under the "Events and Presentations" section.

REHOVOT, Israel and WILMINGTON, Del., June 02, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations, today announced that it will participate in a “Fireside Chat” presentation at the Jefferies Healthcare Conference, to take place June 8-10, 2022, in New York, NY. The company will also be available for one-on-one meetings with institutional investors at the conference.

Details on the presentation can be found below:

Date:	Friday, June 10, 2022
Time:	12:15 – 12:40 PM EST
Format:	Fireside Chat
Location:	Marriott Marquis, 1535 Broadway, NYC

A webcast of the presentation will be available on the “Events and Presentations” section of the Ayala Pharmaceuticals website.

About Ayala Pharmaceuticals
Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. Ayala’s approach is focused on predicating, identifying and addressing tumorigenic drivers of cancer through a combination of its bioinformatics platform and next-generation sequencing to deliver targeted therapies to underserved patient populations. The company has two product candidates under development, AL101 and AL102, targeting the aberrant activation of the Notch pathway with gamma-secretase inhibitors to treat a variety of tumors including Adenoid Cystic Carcinoma, T-cell Acute Lymphoblastic Leukemia (T-ALL), Desmoid Tumors and Multiple Myeloma (MM) (in collaboration with Novartis). AL101, has received Fast Track Designation and Orphan Drug Designation from the U.S. FDA and is currently in a Phase 2 clinical trial for patients with ACC (ACCURACY) bearing Notch activating mutations. AL102 is currently in a Pivotal Phase 2/3 clinical trials for patients with desmoid tumors (RINGSIDE) and is being evaluated in a Phase 1 clinical trial in combination with Novartis’ BMCA targeting agent, WVT078, in patients with relapsed/refractory Multiple Myeloma. For more information, visit www.ayalapharma.com.

Contacts:

Investors:
Joyce Allaire
LifeSci Advisors LLC
+1-617-435-6602
jallaire@lifesciadvisors.com

Ayala Pharmaceuticals:
+1-857-444-0553
info@ayalapharma.com

FAQ

What is Ayala Pharmaceuticals' presentation schedule for the Jefferies Healthcare Conference?

Ayala Pharmaceuticals will present on June 10, 2022, from 12:15 PM to 12:40 PM EST.

Where is the Jefferies Healthcare Conference taking place?

The conference is taking place at the Marriott Marquis in New York, NY.

What is the main focus of Ayala Pharmaceuticals?

Ayala Pharmaceuticals focuses on developing small molecule therapeutics for patients with rare and aggressive cancers.

What are the names of Ayala Pharmaceuticals' product candidates?

The product candidates are AL101 and AL102.

What designations has AL101 received from the U.S. FDA?

AL101 has received Fast Track Designation and Orphan Drug Designation from the U.S. FDA.

When is the webcast for Ayala Pharmaceuticals' presentation available?

The webcast will be available on Ayala's website under the "Events and Presentations" section.